Last reviewed · How we verify
NCT07453927: CGU01_BL
Blue Light for Donor Site Healing in Burn Patients
NA trial testing Photobiomodulation with blue light in Donor Site Complication in 25 participants. Currently enrolling.
31 July 2026
Quick facts
| Lead sponsor | AUSL Romagna Rimini |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 25 |
| Start date | 29 September 2025 |
| Primary completion | 31 July 2026 |
| Estimated completion | 28 September 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Photobiomodulation with blue light
Conditions studied
- Donor Site Complication — all drugs for Donor Site Complication →
- Burn — all drugs for Burn →
- Photobiomodulation Therapy — all drugs for Photobiomodulation Therapy →
- Blue Light — all drugs for Blue Light →
Sponsor
AUSL Romagna Rimini — full company profile →
Who can join
18 and older, any sex, with Donor Site Complication or Burn. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn whether blue light (BL) photobiomodulation can improve the healing of donor site (DS) wounds in patients with burn injuries who are treated surgically. This study will investigate whether adding BL therapy to the usual treatment can improve healing and patient outcomes in adult patients with intermediate and deep burns. The main questions it aims to answer are: * Does the use of BL therapy combined with standard treatment reduce the healing time of DS compared with standard treatment alone? * Does BL therapy improve wound conditions, reduce pain, and decrease signs of infection during the healing process? * Is BL therapy safe and well tolerated when applied to DS? * Does the treatment improve the long-term quality of the scar after healing? Researchers will compare DS areas treated with standard care alone to DS areas treated with standard care plus BL therapy to see whether BL improves healing outcomes. Each participant will serve as their own comparison: two different DS areas on the same patient will receive the two different treatments. Participants will: * Receive the standard treatment for DS, which includes routine wound care and dressing * Receive BL therapy on one DS area in addition to the standard treatment, while another DS area will receive standard treatment alone * Attend regular clinical evaluations where clinicians will assess wound healing and the condition of the wound bed * Report their pain levels using a simple numeric scale during the healing period * Undergo skin swabs to detect possible signs of infection * Be monitored for any local side effects, such as redness, burning sensation, warmth, itching, or skin irritation related to the light treatment After the DS have completely healed, participants will return for follow-up visits at 1 month and 3 months. During these visits, researchers will evaluate the quality of the scars and monitor for any late side effects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07453927
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Donor Site Complication
Currently open trials in the same condition.
- NCT07057557 — Aloe Vera vs Paraffin Tulle Dressings for Pain Management in Split Thickness Skin Graft Donor Sites · NA · recruiting
Other AUSL Romagna Rimini trials
Trials by the same sponsor.
- NCT07172061 — Sigh in Pressure Support Ventilation to Detect Respiratory System Compliance and Lung Recruitability · NA · completed
- NCT06639100 — This Will Be an Observational, Exploratory Study Targeting a Population of Subjects with Diabetes from 4 Different Geogr · active not recruiting
- NCT05306652 — Exercise in Extended Oncogene Addicted Lung Cancer in Active Treatment · NA · recruiting
- NCT04839445 — ESP vs TAP in Total Laparoscopic Hysterectomy · NA · completed
- NCT04729049 — Erector Spinae Block vs Morphine in Vertebral Fixation · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07453927 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AUSL Romagna Rimini
- Last refreshed: 6 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07453927.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing